Who
William D. Young
Director
Company insider
Files Form 4 as: Director, Autolus Therapeutics; Director, Praxis Precision Medicines; Director, Theravance Biopharma; Director, Vertex Pharmaceuticals; Director, BioMarin Pharmaceutical; Director, Innoviva; Chairman and CEO, Monogram Biosciences; Director, Human Genome Sciences.
In numbers
- Trades disclosed
- 106
- Buys
- 1
- Sells
- 5
- Bought
- $106K
- Sold
- $11.3M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 7 Apr 2006
- Last trade
- 29 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 26 Jun 2025filed 27 Jun 2025 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,520 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,566 at $0.00 | filing |
| 12 Jun 2023filed 14 Jun 2023 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,981 at $0.00 | filing |
| 26 May 2022filed 27 May 2022 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,753 at $0.00 | filing |
| 26 Apr 2022filed 28 Apr 2022 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 26 Apr 2022filed 28 Apr 2022 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —9,852 at $0.00 | filing |
| 8 Jun 2021filed 9 Jun 2021 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,343 at $0.00 | filing |
| 13 May 2021filed 7 Jul 2021 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code J | —28,473 at $0.00 | filing |
| 27 Apr 2021filed 29 Apr 2021 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —9,828 at $0.00 | filing |
| 27 Apr 2021filed 29 Apr 2021 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 1 Jun 2020filed 3 Jun 2020 | VRTX Vertex Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,527 at $0.00 | filing |
| 28 Apr 2020filed 30 Apr 2020 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code A | —6,635 at $0.00 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name William D. Young; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.